wild/fever

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to isolated and purified antigen which is expressed by a wild-type E. risticii strain and is specific to the strain. The present invention also relates to nucleic acid constructs which encode the antigen, expression

This is the U.S. national stage of International application PCT/EP2011/002624, filed May 18, 2011 designating the United States and claiming priority to DE 10 2010 017 006.2, filed May 18, 2010, EP 10075207.0, filed May 18, 2010, EP 10075205.4, filed May 18, 2010, EP 10075206.2, filed May 18, 2010,

FIELD This disclosure concerns recombinant RVF viruses comprising deletions in viral virulence genes. These recombinant viruses can be used as vaccines to prevent RVF virus infection. This disclosure further relates to a reverse genetics system used to generate recombinant RVF

FIELD This disclosure concerns recombinant RVF viruses comprising deletions in viral virulence genes. These recombinant viruses can be used as vaccines to prevent RVF virus infection. This disclosure further relates to a reverse genetics system used to generate recombinant RVF

FIELD This disclosure concerns recombinant RVF viruses comprising deletions in viral virulence genes. These recombinant viruses can be used as vaccines to prevent RVF virus infection. This disclosure further relates to a reverse genetics system used to generate recombinant RVF

BACKGROUND OF THE INVENTION The present invention relates to the pharmaceutical composites of the suppository for fever and influenza and their pharmaceutical methods, more particularly, to an anti-pyretic and anti-influenza suppository, which combines all the advantages of traditional Chinese

INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ELECTRONICALLY Incorporated by reference in its entirety herein is a computer-readable nucleotide/amino acid sequence listing submitted concurrently herewith and identified as follows: One 60,213 bytes ASCII (text) file named "713667_ST25.txt,"

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to the characterization of the role that glycosylation of the transmembrane glycoprotein E2 of highly virulent Classical Swine Fever Virus (CSFV) strain Brescia plays during infection in the natural host and to the

FIELD Various embodiments described herein relate to live attenuated viral vaccines and systems and methods for making and administering such vaccines. BACKGROUND In the discussion that follows, reference is made to certain structures and/or methods. However, the following references should not be

FIELD Various embodiments described herein relate to live attenuated viral vaccines and systems and methods for making and administering such vaccines. BACKGROUND In the discussion that follows, reference is made to certain structures and/or methods. However, the following references should not be

FIELD Various embodiments described herein relate to live attenuated viral vaccines and systems and methods for making and administering such vaccines. BACKGROUND In the discussion that follows, reference is made to certain structures and/or methods. However, the following references should not be